— Know what they know.
Not Investment Advice

2252.HK

Shanghai MicroPort MedBot (Group) Co., Ltd.
1W: -4.2% 1M: -16.2% 3M: -2.2% YTD: -7.8% 1Y: +30.1% 3Y: -29.4%
HK$25.18 ($3.22)
+1.00 (+4.14%)
 
HKSE · Healthcare · Medical - Devices · HK$24.8B
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market CapHK$24.8B ($3.2B)
52W Range13.5-33.7
Volume5,240,582
Avg Volume8,071,077
Beta1.50
Dividend
Analyst Ratings
No analyst coverage
Company Info
CEOChao He
Employees450
SectorHealthcare
IndustryMedical - Devices
IPO Date2021-11-02
Building 1
Shanghai
CN
86 21 3895 4600
About Shanghai MicroPort MedBot (Group) Co., Ltd.

Shanghai Microport Medbot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China and Europe. It offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; Honghu, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR'obot, a Mona Lisa robotic transperineal prostate biopsy system. The company also provides spine surgical robots; trans-bronchial surgical robots for trans-bronchial diagnosis and treatment; TAVR surgical robots for heart valve replacement surgery; and automated needle targeting robotics systems for percutaneous lung biopsy and percutaneous nephrolithotomy. Shanghai Microport Medbot (Group) Co., Ltd. was founded in 2014 and is based in Shanghai, China. Shanghai Microport Medbot (Group) Co., Ltd. operates as a subsidiary of MicroPort Scientific Corporation.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms